Common mistakes with Manufacturer Disclosure Statement for Medical Device Security include treating it as a guarantee of safety, using it without validating the device in your own environment, and failing to review it after firmware or configuration changes. Security teams should compare the statement with actual deployment, network exposure, and compensating controls.
What MDS2 is good for, and what it is not
MDS2 is a supplier disclosure tool, not a security certification. It helps you understand a device’s intended security features, data handling, and dependencies, but it does not prove the device is safe in your environment or that the answers remain true after deployment. Treat it as input for due diligence, not as a substitute for testing, segmentation, or local risk review.
That distinction matters because healthcare environments often inherit risk from the actual network, identity, and maintenance conditions around the device. For a practical baseline on device-focused due diligence, the Medical Device Security Guide is the right starting point, while a broader device-trust lens is reinforced by the Device and IoT Identity Guide.
Common mistakes usually start when teams read MDS2 as a yes-or-no security verdict instead of a snapshot of vendor claims. The statement may be accurate at release time and still be incomplete for your deployment because of local routing, shared VLANs, exposed management interfaces, or changes in configuration, firmware, or supporting services.
Why MDS2 reviews fail in practice
One common failure is comparing MDS2 only to procurement requirements and never to the actual device build. A device can look acceptable on paper while still creating risk through default services, unsupported components, weak access paths, or dependencies on other systems that were not fully captured in the disclosure.
Another mistake is assuming the disclosure stays current after procurement. Medical devices often live for years, and firmware updates, operating system changes, network redesigns, or vendor support shifts can invalidate the original answers. In that sense, MDS2 should be treated like a living record that needs periodic reconciliation against the deployed asset.
A third mistake is reading the statement without cross-checking compensating controls. If the device cannot be patched quickly, the real question is whether segmentation, allowlisting, monitoring, or restricted administrative access reduce the blast radius enough for the clinical use case. That is especially important for internet-connected or edge-adjacent medical equipment, where the exposure model can change rapidly.
How to use MDS2 without overtrusting it
Use MDS2 as a review artifact alongside your own validation, not as the validation itself. The most useful review questions are whether the disclosed security features exist in your version of the device, whether they are enabled in production, and whether your network and operational model preserve the assumptions behind them.
That means validating the device in context: confirm current firmware, confirm configuration state, verify whether remote services are enabled, and check whether compensating controls still hold after maintenance or vendor changes. If the answer depends on a control that is not under your operational control, treat the disclosure as a starting point, not a conclusion.
It also helps to pair the disclosure with lifecycle thinking. When the vendor changes components, libraries, certificates, update paths, or default settings, the security posture can change even if the form itself is unchanged. For connected devices, the broader governance pattern is captured well in the IoT Security Guide, especially where firmware updates, segmentation, and device trust affect the real exposure.
Risk and Threat Considerations
MDS2 mistakes become security problems when teams treat disclosure as proof of resilience and stop looking for the device’s actual attack surface. The main risk is false assurance: a device can appear compliant on paper while still being exposed through management interfaces, stale firmware, weak segmentation, or outdated assumptions about support and patching.
Failure mechanism: Security decisions are made from static supplier claims rather than from the deployed state, so gaps introduced by local configuration, change over time, or missing compensating controls go unseen until the device is probed or compromised.
Impact: That gap can leave clinical equipment easier to disrupt, easier to abuse as a foothold, or harder to recover quickly after an incident, especially when the original disclosure is not revisited after changes.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 and CIS Controls v8 set the governance and control requirements practitioners need to meet.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-53 Rev 5 | RA-5 — Vulnerability Monitoring and Scanning | Validates device exposure and changed risk beyond vendor disclosure |
| CM-2 — Baseline Configuration | MDS2 mistakes often arise when deployed settings drift from the disclosed baseline | |
| AC-4 — Information Flow Enforcement | Network segmentation and controlled flows are central compensating controls for exposed medical devices | |
| Recommendation — Compare disclosed device claims against current vulnerability findings and operational exposure. Maintain approved device baselines and revalidate them after firmware or configuration changes. Enforce network flow restrictions around medical devices to limit blast radius. | ||
| CIS Controls v8 | CIS-4 — Secure Configuration of Enterprise Assets and Software | Medical device security mistakes often stem from unverified or outdated configuration assumptions |
| CIS-12 — Network Infrastructure Management | Compensating controls and exposure review depend on knowing how the device is placed and reachable | |
| Recommendation — Harden device configurations and verify them against the disclosed security posture. Segment medical devices and limit management exposure to reduce operational risk. | ||
Practitioner Guidance
What to verify: Check the exact model, firmware, and configuration in production before relying on the statement. If the device has changed materially since the disclosure was produced, re-review it as part of change management rather than accepting the old record at face value.
Decision rule: If the device is reachable from networks or systems you do not fully trust, require an exposure review and compensating controls review before accepting the MDS2 as sufficient. If you cannot validate the device directly, treat the statement as incomplete evidence.
Common mistake: Teams often file the document after procurement and never revisit it. That is the wrong lifecycle model for medical devices, because patching, configuration drift, and vendor support changes can all alter the security picture without any new paperwork.
Practitioner takeaway: Use MDS2 to inform your risk decision, not to replace it; the security value comes from reconciling the disclosure with the real device, the real network, and the real change history.